Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.47 |
| ▸ | CIT | O14578 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | STK10 | O94804 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 2/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.47 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.47 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 0.47 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12684917 | 0.80 | MAPK1 (0.44) | BRAFCSNK1DMAPK3MAPK1CSNK1E | |
| SCHEMBL27716525 | 0.78 | PTGIR (0.58) | BRAFCSNK1DMAPK3MAPK1MAP4K4 | |
| SCHEMBL14519366 | 0.78 | PTGIR (0.58) | BRAFCSNK1DMAPK3MAPK1MAP4K4 | |
| SCHEMBL4138280 | 0.78 | MAPK1 (0.39) | BRAFCSNK1DMAPK3MAPK1MAP4K4 | |
| SCHEMBL17088198 | 0.77 | BRAF (0.60) | BRAFCSNK1DMAPK3MAPK1MAP4K4 | |
| SCHEMBL16510860 | 0.77 | BRAF (0.38) | BRAFCSNK1DMAPK3MAPK1MAP4K4 | |
| SCHEMBL1892201 | 0.76 | CSNK1D (0.65) | BRAFCSNK1DMAPK3MAPK1MAP4K4 | |
| SCHEMBL6077523 | 0.76 | CSNK1D (0.65) | BRAFCSNK1DMAPK3MAPK1MAP4K4 | |
| SCHEMBL17088200 | 0.76 | MEN1 (0.62) | BRAFCSNK1DMAPK3MAPK1MAP4K4 | |
| SCHEMBL12461278 | 0.75 | BRAF (0.54) | BRAFCSNK1DMAPK3MAPK1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101282960-A | RAF inhibitor compounds and methods | GENENTECH INC (US) | 2008-10-08 | — | — | CN | disclosed |
| EP-1846391-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006084015-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885CSNK1D 531/4885MAPK3 49/4885 |
| US-20060189627-A1 | RAF inhibitor compounds and methods | BRAF, RAF1, ARAF | BRAF 1/4885CSNK1D 892/4885MAPK3 55/4885 |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | BRAF, RAF1, ARAF | BRAF 1/4885CSNK1D 892/4885MAPK3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.